Using proteomics to elucidate pathogenesis and establish new diagnostic or treatment evaluation methods in refractory gastrointestinal diseases
利用蛋白质组学阐明难治性胃肠道疾病的发病机制并建立新的诊断或治疗评估方法
基本信息
- 批准号:23249043
- 负责人:
- 金额:$ 30.62万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (A)
- 财政年份:2011
- 资助国家:日本
- 起止时间:2011-04-01 至 2014-03-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
We identified several serum proteins present at high levels in patients with liver disease or inflammatory bowel disease, including complement component C4 fragment (C4-F), kininogen fragment (Kini-F), apoptosis inhibitor (AIM), and human neutrophil peptide (HNP)-1. Serum C4-F and Kini-F are potentially biomakers for antiviral effects in patients with chronic hepatitis C or diagnosis of nonalcoholic fatty liver disease (NAFLD), respectively. In patients with chronic liver disease, serum AIM levels were associated with liver fibrosis. AIM also appeared to contribute to the pathogenesis of NAFLD. Furthermore, HNP-1 worsened pathological condition in the mouse model of NAFLD and alcoholic liver disease, in addition to ulcerative colitis. Thus, proteomics is a useful tool for identifying proteins that might serve as candidate biomarkers in refractory gastrointestinal diseases, and the identified proteins may be involve in the pathological conditions associated with those diseases.
我们鉴定了几种在肝病或炎症性肠病患者中高水平存在的血清蛋白,包括补体成分C4片段(C4-F)、激肽原片段(Kini-F)、凋亡抑制剂(AIM)和人中性粒细胞肽(HNP)-1。血清C4-F和Kini-F分别是慢性丙型肝炎患者或非酒精性脂肪性肝病(NAFLD)诊断患者抗病毒作用的潜在生物标志物。在慢性肝病患者中,血清AIM水平与肝纤维化相关。AIM似乎也有助于NAFLD的发病机制。此外,除了溃疡性结肠炎之外,HNP-1还使NAFLD和酒精性肝病小鼠模型的病理状况恶化。因此,蛋白质组学是一种有用的工具,用于鉴定可能作为难治性胃肠道疾病的候选生物标志物的蛋白质,并且所鉴定的蛋白质可能参与与这些疾病相关的病理条件。
项目成果
期刊论文数量(28)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
ヒト好中球ペプチド-1はNASH動物モデルの肝線維化を促進する
人中性粒细胞肽-1促进NASH动物模型肝纤维化
- DOI:
- 发表时间:2011
- 期刊:
- 影响因子:0
- 作者:宇都浩文;指宿りえ;坪内博仁
- 通讯作者:坪内博仁
Hepatic fibrosis and apoptosis induced by ethanol administration are exacerbated in human neutrophil peptide-1 transgenic mice
人中性粒细胞肽-1转基因小鼠中乙醇诱导的肝纤维化和细胞凋亡加剧
- DOI:
- 发表时间:2014
- 期刊:
- 影响因子:0
- 作者:Ibusuki R;Uto H;Kozono M;Oda K;Ohshige A;Kumagai K;Mawatari S;Tamai T;Moriuchi A;Oketani M;Ido A;Tsubouchi H
- 通讯作者:Tsubouchi H
Long-term administration of sorafenib and initial dosage per body weight are associated with overall survival in patients with unresectable advanced hepatocellular carcinoma
索拉非尼的长期给药和单位体重的初始剂量与不可切除的晚期肝细胞癌患者的总生存期相关
- DOI:
- 发表时间:2011
- 期刊:
- 影响因子:0
- 作者:Hiramine Y;Uto H;et al
- 通讯作者:et al
Difference in serum complement component C4a levels between hepatitis C virus carriers with persistently normal alanine aminotransferase levels or chronic hepatitis C.
- DOI:10.3892/mmr.2012.924
- 发表时间:2012-08
- 期刊:
- 影响因子:3.4
- 作者:Imakiire K;Uto H;Sato Y;Sasaki F;Mawatari S;Ido A;Shimoda K;Hayashi K;Stuver SO;Ito Y;Okanoue T;Tsubouchi H
- 通讯作者:Tsubouchi H
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TSUBOUCHI Hirohito其他文献
TSUBOUCHI Hirohito的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TSUBOUCHI Hirohito', 18)}}的其他基金
Involvement of apoptosis inhibitory factor of macrophage (AIM) on pathophysiological condition of chronic liver disease
巨噬细胞凋亡抑制因子(AIM)对慢性肝病病理生理的影响
- 批准号:
26670385 - 财政年份:2014
- 资助金额:
$ 30.62万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Analysis for molecular mechanism of hepatitis C virus(HCV)-induced protein associated with persistent HCV infection
丙型肝炎病毒(HCV)诱导蛋白与HCV持续感染相关的分子机制分析
- 批准号:
24659371 - 财政年份:2012
- 资助金额:
$ 30.62万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
A role of hepatocyte growth factor in regulation of hepatic development and differentiation
肝细胞生长因子在肝脏发育和分化调控中的作用
- 批准号:
19209028 - 财政年份:2007
- 资助金额:
$ 30.62万 - 项目类别:
Grant-in-Aid for Scientific Research (A)
Hepatocyte growth factor accelerates proliferation and differentiation of hepatic oval cells in a 2-acetylaminofluorene/partial hepatectomy model in rat
肝细胞生长因子加速大鼠 2-乙酰氨基芴/部分肝切除模型中肝卵圆细胞的增殖和分化
- 批准号:
14370186 - 财政年份:2002
- 资助金额:
$ 30.62万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
A transcriptional factor induced by HGF
HGF 诱导的转录因子
- 批准号:
10470138 - 财政年份:1998
- 资助金额:
$ 30.62万 - 项目类别:
Grant-in-Aid for Scientific Research (B).
Injured Tissue Specific HGF Expression and its Mechanism
损伤组织特异性HGF表达及其机制
- 批准号:
08457171 - 财政年份:1996
- 资助金额:
$ 30.62万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Identification of HGF indncing factor in serum from patients with Liver diseases
肝病患者血清中HGF诱导因子的鉴定
- 批准号:
05454247 - 财政年份:1993
- 资助金额:
$ 30.62万 - 项目类别:
Grant-in-Aid for General Scientific Research (B)
相似海外基金
Evaluating the impact of direct-acting antiviral treatment access policy on chronic hepatitis C prevalence and the undiagnosed proportion
评估直接抗病毒治疗获取政策对慢性丙型肝炎患病率和未确诊比例的影响
- 批准号:
475136 - 财政年份:2022
- 资助金额:
$ 30.62万 - 项目类别:
Operating Grants
Search for novel biomarkers involved in hepatocarcinogenesis and liver fibrosis in patients with chronic hepatitis C
寻找参与慢性丙型肝炎患者肝癌发生和肝纤维化的新型生物标志物
- 批准号:
20K16956 - 财政年份:2020
- 资助金额:
$ 30.62万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation for the liver fibrosis and hepatocellular carcinoma incidence after HCV elimination in patients with chronic hepatitis C
慢性丙型肝炎患者消除HCV后肝纤维化及肝癌发生率评估
- 批准号:
20K08820 - 财政年份:2020
- 资助金额:
$ 30.62万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Analysis of immune responses in patients with chronic hepatitis C after viral clearance
慢性丙型肝炎患者病毒清除后的免疫反应分析
- 批准号:
19K17509 - 财政年份:2019
- 资助金额:
$ 30.62万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Impact of chronic hepatitis C virus (HCV) direct-acting antiviral therapy on extrahepatic manifestations among HIV co-infected British Columbians engaged in clinical care
慢性丙型肝炎病毒 (HCV) 直接抗病毒治疗对从事临床护理的 HIV 合并感染不列颠哥伦比亚省人肝外表现的影响
- 批准号:
391545 - 财政年份:2018
- 资助金额:
$ 30.62万 - 项目类别:
Medicaid Prior Authorization Policies for Chronic Hepatitis C Treatment in Vulnerable Populations
针对弱势群体慢性丙型肝炎治疗的医疗补助预授权政策
- 批准号:
10395933 - 财政年份:2018
- 资助金额:
$ 30.62万 - 项目类别:
Medicaid Prior Authorization Policies for Chronic Hepatitis C Treatment in Vulnerable Populations
针对弱势群体慢性丙型肝炎治疗的医疗补助预授权政策
- 批准号:
9906205 - 财政年份:2018
- 资助金额:
$ 30.62万 - 项目类别:
Real-world effectiveness of direct-acting antiviral therapy for chronic hepatitis C among HIV co-infected Canadians receiving clinical care
直接作用抗病毒治疗对接受临床护理的艾滋病毒合并感染加拿大人慢性丙型肝炎的真实效果
- 批准号:
368162 - 财政年份:2017
- 资助金额:
$ 30.62万 - 项目类别:
Population-level impact of direct-acting antiviral (DAA) therapies for chronic hepatitis C on extrahepatic manifestations
直接作用抗病毒(DAA)治疗慢性丙型肝炎对肝外表现的人群影响
- 批准号:
375866 - 财政年份:2017
- 资助金额:
$ 30.62万 - 项目类别:
Fellowship Programs
Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C
依折麦布作为慢性丙型肝炎安全有效的治疗方法
- 批准号:
10158395 - 财政年份:2017
- 资助金额:
$ 30.62万 - 项目类别: